Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRO761 alone or in combination in MSI-high or dMMR advanced solid tumors
NCT05838768Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 1, open-label trial of HRO761 in solid tumor (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 36 months, Incidence of dose limiting toxicities at Day 28 and 3 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
HRO761
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05838768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838768.